Abbott Laboratories (NYSE:ABT)’s traded shares stood at 5.98 million during the last session, with the company’s beta value hitting 0.72. At the close of trading, the stock’s price was $114.22, to imply a decrease of -1.99% or -$2.32 in intraday trading. The ABT share’s 52-week high remains $121.64, putting it -6.5% down since that peak but still an impressive 19.77% since price per share fell to its 52-week low of $91.64. The company has a valuation of $198.73B, with an average of 5.39 million shares in intraday trading volume over the past 10 days and average of 5.45 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Abbott Laboratories (ABT), translating to a mean rating of 1.76. Of 13 analyst(s) looking at the stock, 0 analyst(s) give ABT a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 12 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 1.34.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Abbott Laboratories (NYSE:ABT) trade information
After registering a -1.99% downside in the last session, Abbott Laboratories (ABT) has traded red over the past five days. The 5-day price performance for the stock is -4.33%, and 1.32% over 30 days. With these gigs, the year-to-date price performance is 3.77%. Short interest in Abbott Laboratories (NYSE:ABT) saw shorts transact 11.83 million shares and set a 2.44 days time to cover.
The extremes give us $50 and $150 for target low and target high price respectively. As such, ABT has been trading -31.33% off suggested target high and 56.22% from its likely low.
Abbott Laboratories (ABT) estimates and forecasts
Looking at statistics comparing Abbott Laboratories share performance against respective industry, we note that the company has underperformed competitors. Abbott Laboratories (ABT) shares are 6.22% up over the last 6 months, with its year-to-date growth rate lower than industry average at 5.18% against 11.50%. Revenue is forecast to grow 12.60% this quarter before jumping 13.30% for the next one. The rating firms project that company’s revenue will grow 4.70% compared to the previous financial year.
Revenue forecast for the current quarter as set by 19 analysts is 11.04B. Meanwhile, for the current quarter, a total of 14 analyst(s) estimate revenue growth to 10.67B.Earnings reports from the last fiscal year show that sales brought in 10.24B and 9.96B respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 7.80% before jumping 7.00% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 19.65% for the past 5-year period. While 2024 is set for a 5.29% return in earnings, projections for the next 5 years are at 9.50% annually.
ABT Dividends
Abbott Laboratories has its next earnings report out on 2025-Jan-22. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Abbott Laboratories has a forward dividend ratio of 2.20, with the share yield ticking at 1.93% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 1.64%.
Abbott Laboratories (NYSE:ABT)’s Major holders
Abbott Laboratories insiders hold 0.53% of total outstanding shares, with institutional holders owning 79.64% of the shares at 80.06% float percentage. In total, 79.64% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 166.35 million shares (or 9.5932% of shares), all amounting to roughly $17.29 billion.
The next major institution holding the largest number of shares is BLACKROCK INC. with 131.13 million shares, or about 7.5619% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $13.63 billion.
We also have Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund as the top two Mutual Funds with the largest holdings of the Abbott Laboratories (ABT) shares. Going by data provided on Jun 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 54.97 shares. This is just over 3.16% of the total shares, with a market valuation of $6.28 billion. Data from the same date shows that the other fund manager holds a little less at 44.65, or 2.57% of the shares, all valued at about 5.1 billion.
